Identification of an immunodominant and highly immunopathogenic determinant in the retinal interphotoreceptor retinoid-binding protein (IRBP) by unknown
IDENTIFICATION OF AN IMMUNODOMINANT AND
HIGHLY IMMUNOPATHOGENIC DETERMINANT
IN THE RETINAL INTERPHOTORECEPTOR
RETINOID-BINDING PROTEIN (IRBP)
By HIROKI SANUI,* T. MICHAEL REDMOND,: SATOSHI KOTAKE,*
BARBARA WIGGERT,1 LI-HONG HU,* HANAH MARGALIT,§
JAY A. BERZOFSKY,11 GERALDJ. CHADER,1 AND IGAL GERY*
From the Laboratories of *Immunology and IRetinal Cell and Molecular Biology, National Eye
Institute; and §Laboratory of Mathematical Biology and IlMetabolism Branch, National Cancer
Institute, National Institutes of Health, Bethesda, Maryland 20892
Autoimmunity to ocular antigens is assumedtoplayamajor roleinthe pathogen-
esis of numerous intraocular inflammatory conditions that are grouped under the
term "uveitis" (1-3). This notion is supported by thefinding that immunization with
ocular components may cause in animals a disease that resembles in many aspects
certain uveitic conditions in man (1-3). The animal disease has been designated ex-
perimental autoimmune uveoretinitis (EAU).' The antigen used in most studies for
EAU induction has been the retinal S antigen (1-4), but we and otherinvestigators
haverecently reported that anotherretinalcomponent, theinterphotoreceptor retinoid-
binding protein (IRBP), is similarly uveitogenic in rats (3, 5-7), mice (8), rabbits
(9), or monkeys (10). IRBP, a glycoprotein of -140 kD, is the major protein in the
interphotoreceptor matrix and is thoughtto function mainly in thetransport ofreti-
noids between the retina and the pigment epithelium (11). In addition to the eye,
IRBP also localizes in the pineal gland (12), an organ that is related to light detec-
tion in many vertebrates (13). Consequently, animals immunized with IRBP often
develop inflammation in the pineal gland (experimental autoimmune pinealitis [EAP])
as well (5, 6, 10).
In a recent study we have isolated several cyanogen bromide fragments ofbovine
IRBP and determined their capacity to induce EAU and EAP (14). Three of the
fragmentsthat exhibitedconsiderable levels ofimmunopathogenicity were localized
to regions within the known sequence ofIRBP (15), thus enabling the selection of
peptide sequences for synthesis and determination ofimmunopathogenicity. One
criterion for peptide selection was the amphipathicity ofthe peptide sequence (16),
as calculated by the algorithm ofMargalit et al. (17). Twooverlappingpeptides, desig-
nated R4 and R9 (residues 1158-1180 and 1154-1180, respectively, according to the
sequence reported by Borst et al. [15]), were found to produce EAU and EAP in
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Lewis rats (18). No immunopathogenicity was detected in seven other synthetic pep-
tides (18) . It is noteworthy, however, that peptides R4 and R9 were immunopatho-
genic only at high doses (>28 nmol/rat), which are approximately four orders of
magnitude higher than that of whole IRBP (5, 7, 19). Significantly, R4 and R9,
as well as the other seven peptides, were found in another study (Redmond, T. M.,
H. Sanui, L.-H. Flu, B. Wiggert, H. Margalit, J. A. Berzofsky, G. J. Chader, and
I . Gery, manuscript submitted for publication) to be nonimmunodominant; namely,
they were not recognized by lymphocytes sensitized against whole IRBP (see refer-
ences 16 and 20 for detailed definition of immunodominance).
While testing additional synthetic peptides, derived from cyanogen bromide frag-
ment CB71 (14), we have identified a determinant that is profoundly immunodominant
in the Lewis rat. This peptide, which consists of residues 1169-1191, is predicted to
be strongly amphipathic (17) and was found to be highly immunopathogenic. This
work records the immunogenic and immunopathogenic capacities ofpeptide 1169-1191
and compares them with the capacities of two related but nondominant peptides,
1158-1180 and 1169-1188 .
Materials and Methods
Antigens.
￿
Bovine IRBP was purified as described in detail elsewhere (21). The IRBP-derived
peptides tested here were synthesized and purified by Applied Biosystems Inc., Foster City,
CA, using the t-BOC chemistry, on a peptide synthesizer (430A; Applied Biosystems, Inc.).
The peptide sequences were derived from the sequence of bovine IRBP, as determined and
reported by Borst et al. (15). The peptides used in the present study included two previously
tested sequences, 1158-1180 (HVDDTDLYLTIPTARSVGAADGS) and 1169-1188 (PTARSV
GAADGSSWEGVGVV). These were compared with the novel sequence 1169-1191 (PTARSV
GAADGSSWEGVGVVPDV). In addition, a series of truncated forms of peptide 1169-1191
were synthesized and used here.
Immunization ofRats.
￿
Male inbred Lewis rats, 8-12 wk old, were supplied by Charles River
Breeding Laboratories, Inc., from the facility in Raleigh, NC. The rats were immunized
by a single injection of IRBP or the peptides, emulsified in CFA, containing Mycobacterium
tuberculosis H37Ra at 2 .5 mg/ml. The emulsion was injected into one hind footpad in a volume
of 0.1 ml containing various amounts of the antigens. An additional adjuvant, Bordetella per-
tussis bacteria (lot 91B; Michigan Department of Public Health, Lansing, MI), was injected
intravenously, 10'° organisms/rat, concurrently with the immunization.
DiseaseMonitoring andAssessment.
￿
Immunized rats were examined daily for clinical ocular
changes (5); disease occurrence and severity were verified by conventional histological exami-
nation (22). Pineal inflammation was determinedby histological examination (22). The severity
of the disease in the two organs was graded according to the intensity of the changes, using
a scale of 0 to 4 (5).
Adoptive Transfer ofDisease.
￿
Draining lymph node or spleen cells from immunized rats were
collected 11-14 d after immunization and were used for adoptive transfer of EAU after their
incubation with the homologous (immunizing) or heterologous antigens. The procedure was
similar to that used in our previous studies (23, 24). Briefly, the lymphoid cells were incubated
with IRBP or the peptides, as indicated, at 10 Ftg/ml, in aliquots of 4 x 106 cells/2 ml in
12-well cluster plates (Costar, Cambridge, MA). After incubation for 3 d the cells were col-
lected, washed, and injected intraperitoneally into naive recipients. The development and
severity of disease were assessed as described above.
Lymphocyte Proliferation Assay.
￿
Lymph node cell responses were measured as described in
detail elsewhere (25). In brief, 3 x 105 lymphoid cells were cultured in triplicate in flat-
bottomed microplates, with or without the tested antigen, in RPMI 1640 medium with 5
FCS, in a total volume of 0.2 ml. The cultures were incubated for a total period of 90 h,
with a pulse of [3H]thymidine (0.5 /ACi/10 u1/well) given for the last 16 h. The data arepresented as stimulation index (SI) values (SI = mean cpm in cultures with stimulus/mean
cpm in control cultures without stimulus). Controlcultures incorporated [3H]thymidine with
levels of 500-2,000 cpm.
Results
ImmunodominanceofPeptide 1169-1191:RecognitionbyLymphocytesSensitizedagainst Whole
IRBP. Theimmunodominance ofIRBP-derived peptides wasdetermined according
to theircapacity to stimulatelymphocytessensitized againstwhole IRBP Fig. 1 sum-
marizes a typical experiment in which lymph node cells from rats immunized with
whole IRBP were tested for responsiveness in culture toward the protein, peptide
1169-1191, andtwo otherpeptides, 1158-1180, which overlapspartiallywith 1169-1191,
and 1169-1188, whichis atruncated form of 1169-1191. Vigorous responseswere stimu-
latedbyawide range ofconcentrationsof 1169-1191, withproliferation levels similar
to thosestimulated by thewholeprotein. In contrast, no responses could bedetected
in cultures incubated with the other two peptides. These data, thus, show that pep-
tide 1169-1191 isprofoundly immunodominant whilethe other two peptides arenon-
dominant.
Recognition of Whole IRBP by Lymphocytes Sensitized against 1169-1191.
￿
The im-
munodominance ofpeptide 1169-1191 was further depicted by the capacity oflym-
phocytes sensitized against it to recognize the whole IRBP molecule. As shown in
Table 1, lymphocytes sensitized against peptide 1169-1191 proliferated vigorously
when incubated with either this peptide or whole IRBP Conversely, no such dual
crossrecognition with IRBP was found with peptide 1158-1180, which is immuno-
genic but nondominant. Thus, lymphocytes sensitized against peptide 1158-1180,
which reacted well against the immunizing peptide, failed to respond against whole
IRBP Marginal or no response to either whole IRBP or the immunizing peptide
wasdetected inculturesoflymphocytesfrom ratsimmunizedagainstpeptide 1169-1188,
which is, therefore, essentially nonimmunogenic in Lewis rats.
ImmunodominanceofPeptide1169-1191. Cross-stimulation ofLymphocytesforAdoptive Transfer
ofEAUIEAP The disease induced by IRBP may be transferred to naive rats by
lymphocytes sensitized against the protein, after a mandatory stimulation ofthese
cells by the homologous or crossreacting antigens (19, 24). Peptides 1158-1180 and
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FIGURE 1. Lymphocytes sen-
sitized againstwholeIRBP rec-
ognize the immunodominant
peptide 1169-1191 but not the
nondominant peptides. Thelym-
phocytes were obtained from
draining lymphnodesofLewis
rats, 14 d after immunization
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TABLE I
Immunodominance of Peptides: Crossrecognition with Intact IRBP
by Sensitized Lymphocytes
* Lewis rats were injected with 0.5 nmol whole IRBP, or 100 nmol peptides .
1 IRBP was tested at 0.6 AM and the peptides at 40 MM .
9 Stimulation index.
1169-1191 induce EAU and EAP in Lewis rats (reference 18 and data recorded below)
and the diseases induced by these peptides were also found transferrable to naive
recipients after activation in vitro (Table II). The system of disease transfer has
provided, therefore, an additional assay to test the immunodominance of IRBP-
derived peptides, according to their capacity to cross-stimulate lymphocytes in cul-
ture for disease induction in naive recipients. As shown in Table II, lymphocytes
sensitized in vivo against whole IRBP were stimulated for disease induction by ei-
ther IRBP or peptide 1169-1191, but not by peptide 1158-1180. The crossrecognition
between whole IRBP and peptide 1169-1191 was also demonstrated by the stimula-
tion with IRBP of lymphocytes sensitized against 1169-1191. In contrast, lympho-
cytes sensitized against 1158-1180, which produced disease after stimulation in vitro
with this peptide, had no pathogenic activity after incubation with whole IRBP Peptide
1169-1188 is not immunopathogenic in Lewis rats (see below) and it did not activate
in this assay lymphocytes sensitized against IRBP or 1169-1191 (data not shown).
It is ofnote that in spite ofthe differences in immunodominance between peptides
1169-1191 and 1158-1180, lymphocytes sensitized against these two molecules exhibited
a similarity in their capacity to transfer disease after stimulation in vitro with the
TABLE II
Immunodominance of Peptides: Cross-stimulation of Lymphocytes
for Adoptive Transfer ofEAU
Data collected with recipient rats injected with 50-100 x 106 spleen or lymph
node cells from immunized rats, after incubation in culture with the antigens
as indicated.
Immunizing
antigen
Antigen
in culture Incidence
EAU
Onset day
(mean)
Severity
(mean)
IRBP IRBP 8/8 3.9 2.0
1158-1180 0/4 - 0
1169-1191 5/5 4.6 1 .8
1158-1180 IRBP 0/3 - 0
1158-1180 9/9 4.3 1 .3
1169-1191 IRBP 6/7 4.0 1 .2
1169-1191 7/9 5 .1 1 .5
Immunizing - - Antigen in culture-
antigen* IRBP 1158-1180 1169- 1188 1169-1191
IKBp
-
28.06
_ _
0.8 1 .1 10.3
1158-1180 1 .6 22.8 ND 0.9
1169-1188 1 .3 ND 2 .4 1 .5
1169-1191 8.2 0.6 1 .8 20.7homologous peptide. Furthermore, thedisease-inducing capacityoflymphocytes sen-
sitized against the two peptides resembled that of lymphocytes sensitized against
whole IRBP (Table II).
ImmunopathogenicityofPeptide 1169-1191.
￿
LewisratsdevelopedEAUandEAP after
immunization with 1169-1191 at doses as low as 0.024 nmol (Table 111). The min-
imal immunopathogenic doseof1169-1191 islowerbyfarthan that ofthe nondominant
peptide, 1158-1180, which is -28 nmol/rat (18). The high immunopathogenicity of
1169-1191 is also indicated by the earlyonset ofEAU, as soon as 8 or 9 d after immu-
nization (Table III and data not shown). The short onset time ofEAU induced by
1169-1191 resemblesthat ofthe disease induced bywhole IRBP (5, 7) andis remark-
ably shorter than that of EAU induced by peptide 1158-1180 (,>12 d) (18).
Fig. 2 demonstrates the typical histopathological changes in the eyes and pineal
gland of rats immunized with peptide 1169-1191. Inflammatory infiltration is seen
in most ocular tissues (Fig. 2, b, c, and e), as well as in the pineal gland (Fig. 2f).
Of particular interest are the changes in the posterior segment of the eye, which
include retinal detachment with accumulation offibrinous and cellular exudate in
the sub-retinal space, as well as severe damage to the photoreceptorcell layer (Fig.
2, b and c). The changes observed in both the eyes and pineal glands of rats im-
munized with 1169-1191 closely resemble those routinely seen in rats immunized
with whole IRBP (see references 5-7 for comparison). Another feature common to
rats immunized with peptide 1169-1191 and whole IRBP is the "acute" kinetics of
the ocular disease: afteran early onset, the inflammation subsided rapidly and usu-
ally disappeared within 8-10 d later.
Immunogenicity ofPeptide1169-1191.
￿
In parallel with its high levelofimmunopatho-
genicity, peptide 1169-1191 was found to be a potent immunogen in Lewis rats, as
demonstrated by its capacity to induce specific cellular immunity at very lowdoses.
The immune response was measured by the lymphocyte proliferation assay and the
results ofa representative experiment are shown in Fig. 3. Positive responses were
obtained with lymphnode cells from rats immunized with 1169-1191 at doses aslow
as 0.1 nmol. It is also noteworthy that a good correlation was found between the
minimal immunogenic and immunopathogenic doses of peptide 1169-1191. Thus,
EAU was observed in this and in other experiments only in rats that developed de-
tectable immune response to the peptide (data not shown).
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TABLE III
Immunopathogenicity of Peptide 1169-1191 in Lewis Rats
Injected
dose
nmol/rat
Incidence
EAU
Onset day
(mean)
Severity
(mean)
EAP
Incidence
Severity
(mean)
75 2/2 9.0 1 .5 2/2 2.5
15 4/4 10.2 1 .2 2/2 2.5
3 3/3 11 .0 1 .8 3/3 1 .3
0.6 7/7 10.3 1 .6 3/3 2.0
0.12 7/7 11.1 1 .6 4/5 2.0
0.024 1/5 15.0 1 .0 1/2 1 .0
0.005 0/5 - 0 0/2 01952 IMMUNODOMINANCE AND IMMUNOPATHOGENICITY OF PEPTIDES
FIGURE 2 .
￿
Histopathological changes in eyes and pineal gland of rats immunized with peptide
1169-1191 . (a) Posteriorsegment of an eye of a normal rat, showing the typical stratiform mor-
phology ofthis segment . V, vitreous ; G, ganglion celllayer ; BP, bipolar celllayer; PR, photoreceptor
cell layer (which is composed of the nuclear and outer segment layers) ; C, choroid; S, sclera .
(b) Posterior segment ofa rat at the peak ofEAUinduced by peptide 1169-1191 (13d afterimmu-
nization with 1 nmol) . The retina is detached, edematous, and infiltrated with inflammatory
cells . The photoreceptor layer is severely damaged, with almost acomplete loss ofthe outer seg-
ments . Accumulation of cellular and fibrinous exudate is seen in the sub-retinal space (SRS) .
Also, a few inflammatory cells are seen in the vitreous . (t) Posterior segment of a rat at a late
stage ofEAU induced by peptide 1169-1191 (16 d after immunization with 1 nmol) . The retina
is detached but contains fewer inflammatory cells . The photoreceptor cell layer is virtually de-
stroyed . Cellular and fibrinous exudate is present in the sub-retinal space. (d) Anterior segment10
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FIGURE 3. Proliferation re-
sponsesof lymphnode cellsfrom
rats immunized with different
dosesof peptide 1169-1191 . The
lymphnodeswere collected 14 d
after immunization.
Identification ofthe Active Epitope ofPeptide 1169-1191.
￿
As mentioned above, mar-
ginal or no immunological capacities were found in peptide 1169-1188, which com-
prises the 20 residues at the NH2 terminus ofpeptide 1169-1191. Peptide 1169-1188
was also found tobe nonimmunopathogenic(seeTable IV). Thesefindings indicate,
therefore, that the epitope responsible for the,immunological activities of peptide
1169-1191 is localized atthe COOH terminus ofthispeptide. To determine the min-
imal sequence carrying the immunological activities ofpeptide 1169-1191, a series
oftruncated forms ofthis peptide were synthesized andexamined fortheircapacity
to induce disease and to exhibit immunodominance, as shown by the capacity to
stimulate in culture lymphocytes sensitized against whole IRBP
Table IV summarizes thedata ofexperiments inwhich theimmunopathogenicity
ofthe truncated peptides was tested in Lewis rats. Peptides 1173-1191 (19 residues)
and 1177-1191 (15 residues) resembled peptide 1169-1191 in their immunopathoge-
nicity, with the minimal disease-producing dose of 0.1 or even 0.01 nmol/rat. De-
creased levels ofimmunopathogenicity were demonstrated by the shorter peptides,
1181-1191 (11 residues) and 1182-1191 (10 residues), with minimal immunopathogenic
doses of ti1 and -10 nmol/rat, respectively. On the other hand, no pathogenic ac-
tivity was detected inpeptide 1183-1191 (nine residues) or inanyofthe shorter peptides.
A complete correlation was found between the immunopathogenicity ofthetrun-
cated peptides and their capacity to stimulate proliferation by lymphocytes sensi-
tized against whole IRBP. Atypical experiment is shown in Fig. 4. Peptides 1173-1191
and 1177-1191 resembled 1169-1191 in their stimulatory activity (not shown), while
peptides 1181-1191 and 1182-1191 demonstrated gradually decreasing stimulatoryca-
pacities for the IRBP-sensitized lymphocytes. No response could be detected, how-
ever, in cultures incubated with peptides 1183-1191 or 1184-1191.
of an eye of a normal rat, showing the major structural components: Co, cornea; I, iris; CB,
ciliary body. (e) Anterior segmentofan eyeofaratat thepeakof EAUinducedby peptide 1169-1191
(13 dafter immunization with 1 nmol). Inflammatory exudateoccupies thechambers ofthis seg-
ment and inflammatory cells infiltrate the iris, the ciliary body, and even the cornea. The iris
is attached to the cornea. No apparent changesareseen,however, in thelens (L). (/)Pineal gland
of a rat, 16 d after immunization with 1 nmol of peptide 1169-1191 . Inflammatory infiltration
occurs throughout thepineal tissue.All sections arestained with hematoxylin andeosin (x 100).1954 IMMUNODOMINANCE AND IMMUNOPATHOGENICITY OF PEPTIDES
TABLE IV
Immunopathogenicity of Truncated Forms of Peptide 1169-1191
" Residues .
1 Disease detected only by histological examination.
Discussion
This studyhas identified an immunodominant epitope ofthe IRBP molecule that
is exceedingly immunogenic and immunopathogenic in the Lewis rat. In addition,
data recorded here highlight the usefulness of the experimental system used in this
and in previous studies. In particular, this experimental system allows for the first
time an analysis of the relationships between immunodominance, immunogenicity,
and immunopathogenicity ofdifferent peptidedeterminants of an organ-specific pro-
tein. This analysis became feasible when four types ofpeptides were identified among
the IRBP-derived determinants, as summarized in Table V. In addition to the im-
munodominant peptide, 1169-1191, three types of nondominant peptides were
identified, according to their capacity to induce immune response and EAU/EAP
Peptide Dose
nmol/ral
Incidence
EAU
Onset day
(mean)
Severity
(mean)
1169-1191 (23)* 10 3/3 9 .7 2.0
1 3/3 11 .0 1 .7
0.1 3/3 11 .7 1 .7
0.01 0/3 - 0
1173-1191 (19) 10 3/3 10 .3 1 .7
1 3/3 11 .0 1 .5
0.1 3/3 11 .7 1 .3
0.01 0/3 - 0
1177-1191 (15) 10 3/3 9 .7 2.0
1 3/3 11 .0 1 .7
0 .1 3/3 14 .3 1 .0
0 .01 1/3 14.0 1 .0
1181-1191 (11) 10 3/3 9 .5 1 .5
1 3/3 11 .7 1 .1
0 .1 0/3 - 0
0 .01 0/3 - 0
1181-1191 (10) 100 5/5 13 .4 1 .0
10 2/3 17 .5 1 .0
1 11/3 NA 0 .5
0 .1 0/3 - 0
1183-1191 (9) 100 0/3 - 0
10 0/4 - 0
1184-1191 (8) 100 0/3 - 0
10 0/4 - 0
1185-1191 (7) 100 0/3 - 0
10 0/4 - 0
1169-1188 (20) 100 0/3 - 0
10 0/3 - 0SANUI ET AL.
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in Lewis rats. The data collected with the various peptides demonstrate the clear
association between immunodominance and the level of immunological activities
of the peptides. In particular, as recorded in this work, the immunodominant pep-
tide 1169-1191 exhibits immunological capacities that are clearly superior to all of
the nondominant peptides.
The feature of immunodominance was determined in the present study by the
capacity ofthe peptides to stimulatelymphocytes sensitized against thewhole IRBP
protein. In addition to the conventional lymphocyte proliferation assay(Fig. 1), the
immunodominance ofpeptides was determined hereby theircapacity to cross-stimulate
IRBP-sensitized lymphocytes and make them capable to adoptively transfer disease
to naive recipients (Table II). It is also noteworthy that the intact IRBP protein was
recognized in culture only by lymphocytes sensitized against the immunodominant
peptide 1169-1191, but notby lymphocytes sensitized against the nondominantpep-
tides (Tables I and II). This findingis not clear and could be attributed to the pro-
cessing of the native protein, which either does not produce the nondominant pep-
tides, or produces them in association with hindering structures that interfere with
binding to the TCR or the MHC molecule on APC. A similar finding has been
recently reported with the myoglobin system (26).
The most striking difference observed here between the immunodominant
(1169-1191) and nondominant (1158-1180) peptides has been the much smaller dose
of the dominant peptide needed for induction of immune response and disease in
TABLE V
Features of the Four Types of IRBP-derived Peptides
FIGURE 4.
￿
Recognition oftrun-
cated forms ofpeptide 1169-1191
by lymph node cells sensitized
against whole IRBP. The 11-
and 10-residue peptides reacted
Peptides
￿
at higher concentrations than
e
￿
1189-1191
￿
the parent peptide, whereas the
1181-1191
￿
nine- and eight-residue peptides
s
￿
1182-1191 were not recognized by the
IRBP-sensitized lymphocytes.
11 es-1191
￿
The lymph nodes were collected
°
￿
11ea_1191
￿
from rats 14 d after immuniza-
tion with 50 P,g bovine IRBP.
Features relevant to the immune responses in Lewis rats.
* The sequences and immunological activities ofthese peptides are recorded (reference 18 and
Redmond, T. M ., H. Sanui, L.-H. Hu, B. Wiggert, H. Margalit, J. A. Berzofsky, G. J .
Chader, and I. Gery, manuscript submitted for publication).
Type Peptide Immunodominance Immunogenicity Immunopathogenicity
1 1169-1188 No No No
II Majority of
tested peptides* No Yes (low) No
III 1158-1180 No Yes (low) Yes (low)
IV 1169-1191 Yes Yes (high) Yes (high)1956 IMMUNODOMINANCE AND IMMUNOPATHOGENICITY OF PEPTIDES
Lewis rats. Thus, the minimal dose of1169-1191 fortheseactivities(0.02-0.1 nmol/rat)
(Fig. 3 and Table III) is "1,000 times smaller than that of peptide 1158-1180 (=28
nmol/rat) (reference 18 and Redmond, T M., H. Sanui, L.-H. Hu, B. Wiggert,
H. Margalit, J. A. Berzofsky, G. J. Chader, and I. Gery, manuscript submitted for
publication). The superiority ofthe immunodominant peptide in initiating immune
responses is not completely understood andmay be attributedto at least twomecha-
nisms: first, the immunodominantpeptidemaybind with greater affinity tothe MHC
antigen on the APC than does the nondominant peptide. Data supporting this no-
tion have been provided by recent studies ofGrey, Gefter, Unanue, and their co-
workers (27-29). The second mechanism could involve the polyclonality of the re-
sponse to the immunodominant peptide. Several reports have recently shown that
immunodominant epitopes are the focus fora diversity ofT cells with different fine
specificities (20, 30, 31). These two hypothetical mechanisms are not mutually ex-
clusive and both could facilitate the immune response toward the exceedingly low
doses of the immunodominant epitope observed in our study.
Anotherdifference between peptides 1169-1191 and 1158-1180, which could be at-
tributed to the immunodominance of the former, is depicted by the kinetics and
histopathological changes ofthe ocular diseases these peptides induce in Lewis rats.
Thus, the disease induced by-1169-1191 is indistinguishable by both these features
from the disease induced by whole IRBP (5-7). On the other hand, the EAU in-
duced by 1158-1180 has a later onset and exhibits more "chronic" histopathological
changes than the disease induced by intact IRBP (18).
In contrast to the striking differences between the immunogenicity and im-
munopathogenicityofpeptides 1169-1191 and 1158-1180, lymphocytes sensitized against
these two peptides were similar in their capacity to adoptively transfer EAU and
EAP into naiverecipients (Table II). This finding suggests, therefore, that thediffer-
encebetweenimmunodominant and nondominant epitopesliesmainly attheafferent
limb (i.e., the sensitization phase) of the immune response.
The identification ofimmunodominant and nondominant determinants ofIRBP
in the present study made it possible to analyze these peptides forfeatures common
for immunodominant epitopes, i.e., amphipathicity (16, 17, 20) and the existence
of"immunogenic motifs," as defined by Rothbard and Taylor (32). Amphipathicity
has been a major criterion for selection ofIRBP-derived peptides (18) and peptide
1169-1191 contains a 31o helix, with a high amphipathic score of 24.2, using the al-
gorithm of Margalit et al. (17). In addition, this peptide contains two sequences
that meet the immunogenic motif criterion of Rothbard and Taylor (GAAD and
GVVPD). Two such motifs (DLYLT and GAAD) are also located on peptide 1158-
1180, but the amphipathicity of this nondominant peptide is quite low (it includes
only one block of a predicted amphipathic segment: TARSVGAADGS). On the
otherhand, peptide 1169-1188, which is nondominant and essentially immunologi-
cally inactive in the Lewis rat, is part ofthe same amphipathic segment as 1169-
1191, has an amphipathic score of 17.9, and contains one immunogenic motif
(GAAD). It is conceivable, therefore, that in addition to the two aforementioned
features, immunodominant peptides have other properties that promote their im-
munogenic capacities in certain hosts. As mentioned above, these properties could
include the efficient binding to the specific MHC antigen on APC of that host and
the polyclonality of the responding lymphocyte population. The additional threeSANUI ET AL.
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residues, PDV, which distinguish 1169-1191 from 1169-1188, presumably participate
in one or both of these properties.
The minimal immunogenic and immunopathogenic dose of peptide 1169-1191 in
the Lewis rat (0.02-0.1 nmol/rat), is -10 times higher than that of whole IRBP
(=0.002 nmol/rat) (5, 7, 19). This finding suggests that the large IRBP molecule
carries more than one immunodominant epitope for Lewis rats. This notion is in
line with the observation that the IRBP molecule consists of four repeats with high
levels of sequence similarity (15). It is possible, therefore, that the homologues of
the active site of 1169-1191 in theotherrepeats arealso immunodominant andpossess
high immunological capacities. This possibility is currently under investigation in
our laboratory.
The minimalimmunopathogenic dose of 1169-1191 is comparable with that ofpep-
tide 68-88 of guinea pig myelin basic protein for induction of experimental allergic
encephalomyelitis in Lewis rats (0.075 nmol/rat) (33). Peptide 68-88 has also been
identified as the immunodominant epitope of myelin basic protein in the Lewis rat
(34). On the other hand, remarkably higher dosesthan those of 1169-1191 were reported
necessary forinductionof EAU and EAP by peptides "M" and"N," which have been
reported to be the immunopathogenic determinants of another retinal protein, S
antigen (35, 36). The immunodominance ofthese two peptides hasnotbeen recorded,
but it is conceivable that these determinants are not immunodominant epitopes of
S antigen.
The active site of peptide 1169-1191 was localized to a 10-residue sequence at the
COOH terminus of the peptide. Significantly, a complete correlation was observed
between the level of immunodominance of the truncated peptides (Fig. 4) and their
immunopathogenicity (Table IV). It is also noteworthy that on a molar basis, the
15-residue peptide (1177-1191) was as active as the 23-residue molecule (1169-1191),
whereas the 10-residue peptide (1182-1191) was -100 times less active (Fig. 4 and
Table IV).
Further studies are currently underway to determine which amino acids of
peptide 1169-1191, in particular at the COOH terminus, are pivotal for its im-
munological activities in the Lewis rat. In other experiments, the immunogenicity,
immunopathogenicity, and immunodominance of peptide 1169-1191 and other
IRBP-derived peptides are being examined in other rat strains as well as in other
species.
Summary
Interphotoreceptor retinoid-binding protein (IRBP), a glycoprotein specific for
the retina and pineal gland, induces inflammatory changes in these two organs in
immunized animals. We report here on the identification of an immunodominant
determinant of bovine IRBP that is highly immunogenic and immunopathogenic
in the Lewis rat. The peptide, which comprises the sequence 1169-1191 of bovine
IRBP, was shown to be immunodominant by its capacity to stimulate lymphocytes
sensitized against whole IRBP A comparison was made between peptide 1169-1191
and anotherpeptide, 1158-1180, which is nondominant but is immunogenic andim-
munopathogenic in the Lewis rat. Peptide 1169-1191 was found to be superior in
its immunological capacities; the minimal dose of 1169-1191 needed to induce cel-
lular immune response or disease in Lewis rats (0.02-0.1 nmol/rat) is =1,000 times1958 IMMUNODOMINANCE AND IMMUNOPATHOGENICITY OF PEPTIDES
smaller than that of 1158-1180. In addition, unlike the ocular disease induced by
1158-1180, the disease produced by 1169-1191 resembled that induced by whole IRBP
in its kinetics and histopathological features. The immunological activity of 1169-1191
in the Lewis rat was localized to the 10 residues at the COOH terminus; no such
activity was exhibited by the truncated peptide 1169-1188, which comprises the 20
residues at the NH2 terminus of the full peptide. The usefulness of this unique ex-
perimental system in analyzing the role of immunodominance in peptide immunoge-
nicity and immunopathogenicity is underscored.
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